Definium Therapeutics, Inc. · NASDAQ:DFTX
Definium Therapeutics — Mind Medicine (MindMed) — Investor Presentation (March 2024)
70 slides from Definium Therapeutics's investor presentation, Mar 7, 2024
Slide 1: MM120 for Generalized Anxiety Disorder Phase 2b Full Topline Data
Exhibit 99.1 MM120 for Generalized Anxiety Disorder (GAD) Phase 2b Full Topline Data ODT PK Bridging Study Breakthrough Therapy Designation March 2024
Slide 2: Disclaimer
Disclaimer This presentation (the “Presentation”) has been prepared by Mind Medicine (MindMed) Inc. (“MindMed”, the “Company”, “we”, “our” or “us) solely for informational purposes. None of MindMed, its affiliates or any of their respective employees, directors, officers, contractors, advisors, memb
Slide 3: Today's Agenda
Today’s Agenda Speaker Topic Rob Barrow Introductory Remarks Chief Executive Officer, MindMed Rakesh Jain, MD, MPH KOL Perspective on Unmet Need in Clinical Professor of Psychiatry and Behavioral Sciences, Texas Tech University Generalized Anxiety Disorder (GAD) & School of Medicine – Permian Basin
Slide 4: Introductory Remarks
Introductory Remarks Robert Barrow Chief Executive Officer
Slide 5: We Aim To Be A Global Leader In Brain Health
We Aim To Be A Global Leader In Brain Health Pipeline Management Diversified pipeline of clinical Expertise in drug development programs targeting and commercialization significant unmet medical needs Research Expected Runway Leveraging decades of preclinical and clinical Expected cash runway throug
Slide 6: Experienced Leadership with a Proven Track Record
Experienced Leadership with a Proven Track Record Strong Experience in 1 Brain Health Innovation 1. Includes Investor Presentation | March 2024 6
Slide 7: MM120 Has the Potential to Address a Large Unmet Need in GAD
MM120 Has the Potential to Address a Large Unmet Need in GAD Opportunity in Generalized Anxiety Disorder (GAD) 1 • GAD is the 2nd most common mental disorder among adults , yet there Potential Best-in-Class are limited treatment options Therapy with Novel MOA • Symptoms may be debilitating and treat
Slide 8: MindMed Research & Development Pipeline
MindMed Research & Development Pipeline Product Candidate Indication Preclinical Phase 1 Phase 2 Phase 3 Registration Psychiatry Programs Generalized Anxiety MM120 1 Disorder (GAD) (Lysergide D-tartrate) Additional Psychiatric 2 Indication MM402 Autism Spectrum 1 Disorder (ASD) (R(-)-MDMA) Early Res
Slide 9: Key Highlights of MM120 Program Updates
Key Highlights of MM120 Program Updates 1 Positive 12-Week Durability in Phase 2b Trial of GAD • Primary and secondary endpoints met with statistical significance • 7.7-point improvement over placebo (d=0.81; p=0.003) • 48% clinical remission rate at Week 12 Breakthrough Therapy Designation • Recogn
Slide 10: Results for MM120 in GAD Delivered on Target Product Profile
Results for MM120 in GAD Delivered on Target Product Profile after Single Dose 1,2 with Significant Improvement in All Endpoints Fast Acting 1.8-point reduction in CGI-S within 24 hours (p<0.0001) 21.9-point improvement in HAM-A at Week 12 (p=0.003) represents Durable Activity further improvement fr
Slide 11: 12-Week Durability Observed with Effect Size Over Double the Standard of Care
12-Week Durability Observed with Effect Size Over Double the Standard of 1,3 Care Key Highlights of Phase 2b 12 Comparative Effect Sizes in GAD Week Results • Maximum observed effect size of 0.81 2 MM120 100 µg 0.81 is more than double the standard of 2,3 care 4 Benzodiazepines 0.38 • Rapid and dura
Slide 12: FDA Has Designated MM120 a Breakthrough Therapy for GAD
FDA Has Designated MM120 a Breakthrough Therapy for GAD MM120 Granted Breakthrough Benefits of Breakthrough Therapy 1 Therapy Designation Designation • • FDA organizational commitment Recognizes GAD as a serious condition involving senior managers • Phase 2b results demonstrate • Intensive guidance
Slide 13: PK Bridging Study Demonstrates Enhanced Product Profile for MM120 ODTs
PK Bridging Study Demonstrates Enhanced Product Profile for MM120 ODTs 1 Comparative PK Profile 2.5 MM120 Capsule Differentiated Performance of MM120 ODTs MM120 ODT 2 2 50% faster onset of action 1.5 3 17% improved bioavailability 1 4 0.5 23% increase in AUC at target conc. AUC 0 5 0 2 4 6 8 10 12 1
Slide 14: Compelling Commercial Opportunity for MM120
Compelling Commercial Opportunity for MM120 Driven by Significant Unmet Need and Proven Pathways to Scale Significant Large unmet need market Significant Established Best-in-class reimbursement Commercial profile framework Potential Large and Strong growing value infrastructure proposition Investor
Slide 15: KOL Perspective on Impact and Unmet Need in GAD
KOL Perspective on Impact and Unmet Need in GAD Rakesh Jain, MD, MPH Clinical Professor of Psychiatry and Behavioral Sciences, Texas Tech University School of Medicine – Permian Basin
Slide 16: Perspective on Impact and Unmet Need in GAD
Perspective on Impact and Unmet Need in GAD • GAD has a negative impact on many aspects of patients’ lives which Increases with severity • GAD is chronic in nature, worsens with time and often precedes additional psychiatric disorders 1 • Anxiety returning to focus as a major driver of brain health
Slide 17: Overview of Generalized Anxiety Disorder
Overview of Generalized Anxiety Disorder Generalized Anxiety Disorder (GAD) Epidemiology of Anxiety •• Prevalent disorder characterized by persistent 10% prevalence has tripled in past two decades and excessive worry about various aspects of life • More prevalent in women than in men (~2:1) • Indivi
Slide 18: GAD Has Negative Impact on Many Aspects of Patients' Lives
GAD Has Negative Impact on Many Aspects of Patients’ Lives which Increases with Severity Mean Health Utilities Index by GAD Severity GAD Impact on Patients 40 < Psychological well-being 35 30 25 Physical functioning 20 15 10 Disease specific quality of life 5 0 Asymtomatic Mild Moderate Severe (HAM-
Slide 19: GAD is Chronic in Nature and Often Precedes Additional Psychiatric Disorders
GAD is Chronic in Nature, Worsens with Time and Often Precedes Additional 1 Psychiatric Disorders Substance use Panic Disorder MDD TIME SINCE ONSET 1. The Critical Relationship Between Anxiety and Depression - 1 May 2020https://doi.org/10.1176/appi.ajp.2020.20030305 Investor Presentation | March 202
Slide 20: Patients Continue to be Underserved by Current Medications
As the Mainstream Focus on Anxiety Returns, Patients Continue to be Underserved by Current Medications Population Recommendation Grade Children and adolescents aged 8 to The USPSTF recommends screening for anxiety in children B 1 18 years and adolescents aged 8 to 18 years. The USPSTF recommends scr
Slide 21: GAD Patients Express a Desire for New Treatment Options
GAD Patients Express a Desire for New Treatment Options 1 Limitations of Current SOC Quotes from GAD Patients They told me the medication would take 6 weeks to Slow Acting work. I didn’t want to feel like this for another 6 weeks If I’m inconsistent with medication, or run out for a day, Non-Durable
Slide 22: Current Treatments Often Aren't Effective or Tolerated
Current Treatments Often Aren’t Effective or Tolerated and Can Require Numerous Cycles of Switching and Dosage Adjustments Primary Care Follow-up Visits, Oral daily Diagnosis + Rx Switching & Dose Patient treatment Adjustments Investor Presentation | March 2024 22 Source:. Company market research.
Slide 23: Decades of LSD Clinical Research in Psychiatric Disorders
Decades of LSD Clinical Research in Psychiatric Disorders Supports its Unique Potential Investor Presentation | March 2024 23
Slide 24: Summary of Full Topline Results from Phase 2b Trial
MM120 LSD-D-tartrate for Generalized Anxiety Disorder (GAD) Summary of Full Topline Results from Phase 2b Trial Daniel R Karlin, MD, MA Chief Medical Officer
Slide 25: Positive 12-Week Topline Results from Phase 2b Study in GAD
Positive 12-Week Topline Results from Phase 2b Study in GAD: Strong Durability 1 of Effect after Single Dose of MM120 2 • Met the primary and all secondary endpoints with statistical significance • MCP-Mod analysis results support dose-response relationship for MM120 in GAD 3,4 • Large observed effe
Slide 26: Phase 2b Trial Utilized Standard GAD Design and Endpoints
Phase 2b Trial of MM120 Utilized Standard GAD Design and Endpoints and was 1 Aligned with FDA Draft Guidance for Drug Class • Standard GAD study design with endpoints that have supported registration for approved drugs • Randomized, double-blind, placebo-controlled, 12-week trial o Single administra
Slide 27: Phase 2b Trial Schematic
1 Phase 2b Trial Schematic 198 participants total (actual) Study MMED008 | MM120 for GAD Week 8 12 -5 to -1 1 2 4 A Phase 2b Dose Optimization Study of a Single Dose of MM120 in Generalized Dose Follow-Up Screening Anxiety Disorder MM120 200 µg KEY ENTRY CRITERIA MM120 100 µg • Men and Women • Ages
Slide 28: Phase 2b Treatment Paradigm: Standalone Drug Effects
Phase 2b Treatment Paradigm: Standalone Drug Effects with No 1 Psychotherapeutic Intervention • Dosing session monitors (DSMs) in the room provide no psychotherapeutic intervention 2 • Delivery protocol consistent with 2023 FDA Draft Guidance • No changes planned to drug delivery between Phase 2 and
Slide 29: Participant Disposition Aligned with Historical Expectations
1 Participant Disposition Aligned with Historical Expectations - Included in FAS population: 100% 200 µg - Completed 12 weeks (n=30) (n=40) - Discontinued early (n=10) 79% 12-week completion rate 2 in high dose groups despite need for follow-up - Included in FAS population: 100% 100 µg - Completed 1
Slide 30: Participant Demographics and Baseline Characteristics
Participant Demographics and Baseline Characteristics Generally Balanced 1 Across Groups MM120 Placebo Demographic (n=194) 25 µg 50 µg 100 µg 200 µg (n=39) (n=36) (n=40) (n=40) (n=39) Mean age (years) 38.0 45.3 42.7 42.1 38.7 Sex, female (%) 51.3% 55.6% 40.0% 70.0% 66.7% Race (% white) 84.6% 80.6% 9
Slide 31: Reductions in HAM-A Score Continued at Week 12
Statistically and Clinically Significant Reductions in HAM-A Score Continued at 1,2 Week 12 HAM-A Change from Baseline 2 0 Change from Baseline • Week 4: -21.3 points • Week 12: -21.9 points -5 2 Improvement over Placebo -10 • Week 4: -7.6 pts, p=0.0004 • Week 12: -7.7 pts, p=0.003 -15 -20 *** *** *
Slide 32: Continued Response and Remission through Week 12
Continued Response and Remission through Week 12 with 65% Clinical 1 Responder Rate and 48% Clinical Remission Rate 2 2 HAM-A Response Rate at Week 12 HAM-A Remission Rate at Week 12 50 48 70 65 45 63 60 56 40 33 50 44 30 28 40 21 31 30 20 20 10 10 0 0 Placebo 25 µg 50 µg 100 µg 200 µg Placebo 25 µg
Slide 33: MCP-Mod Analysis Supports Dose Response Relationship
Primary & Key Secondary Analysis (MCP-Mod) Support Dose Response 1 Relationship for MM120 in GAD 2 Key Takeaways from MCP-Mod Analysis • Statistically significant dose response relationship with multiple model fits • Supports dose selection of 100 µg for subsequent studies in GAD • Pre-specified mod
Slide 34: Rapid and Sustained Improvements in CGI-S
Rapid and Sustained Improvements in Clinical Global Impressions – Severity 1 (CGI-S) Starting on Day 2 and Continuing through Week 12 2 CGI-S Improvement in 100 µg Group CGI-S Scores at Week 12 6 – Severely Ill • Statistically and clinically significant improvement by Day 2 and 5 – Markedly Ill main
Slide 35: Reductions in Comorbid Depression (MADRS) through Week 12
Statistically and Clinically Significant Reductions in Comorbid Depression (MADRS) 1,2 at All Timepoints through Week 12 3 MADRS Change from Baseline 0 2,3 Change from Baseline • Week 4: -18.1 points • Week 12: -18.7 points -5 2,3 Improvement over Placebo -10 • Week 4: -5.7 points, p<0.05 • Week 12:
Slide 36: MM120 was Well-tolerated with Mostly Transient Adverse Events
MM120 was Well-tolerated with Mostly Transient, Mild-to-Moderate Adverse 1 Events Consistent with Drug Class Expectations • Virtually all AEs (99%) were mild-to-moderate in severity Favorable tolerability • Minimal (2.5%) TEAEs led to study withdrawal profile 2 • No drug-related serious adverse even
Slide 37: Most Common TEAEs in High-Dose Groups
Most Common (≥10%) TEAEs in High-Dose Groups Demonstrate Favorable 1,2 Tolerability Profile MM120 Preferred Term Placebo (n=39) 25 µg 50 µg 100 µg 200 µg (n=39) (n=40) (n=40) (n=40) Subjects (%) with AE DD AFT DD AFT DD AFT DD AFT DD AFT Illusion 12 (31) 1 (2.6) 18 (45) 1 (2.5) 24 (60) 1 (2.5) 30 (7
Slide 38: MM120 ODT PK Bridging Study
MM120 LSD-D-tartrate for Generalized Anxiety Disorder (GAD) MM120 ODT PK Bridging Study Daniel R Karlin, MD, MA Chief Medical Officer
Slide 39: PK Bridging Study Demonstrates Enhanced Product Profile for MM120 ODTs
PK Bridging Study Demonstrates Enhanced Product Profile for MM120 ODTs 1 Comparative PK Profile 2.5 MM120 Capsule Differentiated Performance of MM120 ODTs MM120 ODT 2 2 50% faster onset of action 1.5 3 17% improved bioavailability 1 4 0.5 23% increase in AUC at target conc. AUC 0 5 0 2 4 6 8 10 12 1
Slide 40: MM120 ODT PK Bridging Study Schematic
1 MM120 ODT PK Bridging Study Schematic Study MM120-101 | ODT-PK Bridging 29 participants total (actual) A Phase 1, Open-label Study to Compare the Pharmacokinetics of Two Formulations Day -21 to -1 1 2-13 14 15-29 of MM120 in Healthy Volunteers Dose 2 Follow-up Washout Dose 1 Screening MM120 MM120
Slide 41: Comparative PK of MM120 ODT vs Capsule
Comparative PK of MM120 ODT vs Capsule Demonstrates Favorable Profile of 1 MM120 ODTs 2.5 MM120 Capsule MM120 ODT MM120 1 2 PK Parameter MM120 ODT Capsule 1.5 T (hr) 2.25 2.0 max C (ng/mL) 2.63 2.68 1 max AUC (ng*hr/mL) 15.7 18.7 0-∞ 0.5 AUC (ng*hr/mL) 9.7 12.0 >1ng/mL 0 0 2 4 6 8 10 12 14 16 18 20
Slide 42: MM120 ODT Demonstrates Faster Absorption
MM120 ODT Demonstrates Faster Absorption and Shorter Time to Reach Target Concentrations 1.2 MM120 Capsule 1 Differentiated PK Profile of MM120 ODTs MM120 ODT 1 2 50% faster onset of action 0.8 0.6 3 17% improved bioavailability 0.4 4 0.2 23% increased AUC above target conc. AUC 0 0 10 20 30 Time (m
Slide 43: MM120 ODT Demonstrates Improved Bioavailability
1 MM120 ODT Demonstrates Improved Bioavailability 1 Differentiated PK Profile of MM120 ODTs C max 2 50% faster onset of action GMR: 1.02 3 17% improved bioavailability AUC 0-∞ GMR: 1.17 4 23% increased AUC above target conc. AUC 80% 100% 125% GMR Relative to Capsule 1. Company analysis of pharmacoki
Slide 44: MM120 ODT Achieves Increased AUC Above Target Concentration
MM120 ODT Achieves Increased AUC Above Target Concentration 2.4 MM120 Capsule 1 Differentiated PK Profile of MM120 ODTs MM120 ODT 2.2 2 50% faster onset of action 2 1.8 3 17% improved bioavailability 1.6 1.4 4 23% increased AUC above target conc. AUC 1.2 1 0 2 4 6 8 Time (hours) 1. Company analysis
Slide 45: MM120 Commercial Opportunity
MM120 LSD-D-tartrate Commercial Opportunity Francois Lilienthal, MD, MBA Chief Commercial Officer
Slide 46: Key Factors in Place to Drive a Significant Commercial Opportunity
Key Factors are in Place to Drive a Significant Commercial Opportunity for MM120 Significant Large unmet need market Significant Established Best-in-class reimbursement Commercial profile framework Potential Large and Strong growing value infrastructure proposition Investor Presentation | March 2024
Slide 47: Psychiatric HCPs Expect Psychedelics to Transform Treatment
Psychiatric HCPs Expect Psychedelics to Radically Transform the Treatment of 1 Anxiety and Depression % GAD Providers Agree All Providers 2 Spravato Providers 86% 84% 78% 74% 73% 62% Availability of FDA-approved psychedelic Psychedelic treatments will be a valuable I expect psychedelic treatments to
Slide 48: Psychiatrists Impressed by Clinical Activity and Profile of MM120
Majority of Psychiatrists Are Impressed by the Clinical Activity and Overall Profile of MM120 1,2 % of Psychiatrists Impressed by MM120 87% 87% 86% * 73% Overall Clinical Activity Onset of Activity Durability of Activity Overall Impression (Reduction in HAM-A) (CGI-S at Day 2) (HAM-A at Week 12) 1.
Slide 49: Commercial Model Leverages Interventional Psychiatry Model Established by Spravato
MM120 Commercial Model Leverages Proven and Rapidly Expanding Interventional Psychiatry Model Established by Spravato® • >3,500 certified delivery clinics for Spravato® • Proven reimbursement, documentation and logistics pathways • Rapidly expanding uptake with blockbuster projections Source: J&J In
Slide 50: Proven Pathways Already Exist for Patient Care & Reimbursement
Proven Pathways Already Exist for Patient Care & Reimbursement Diagnosis + Rx Treatment Session Drug Patient Psychiatrist / Monitored by Licensed Distributed via Specialty 1 2 Prescribing HCP HCP Pharmacy Reimbursement Payer 1. HCP that is licensed to prescribe medications to patients. 2. HCP that i
Slide 51: Reimbursement Pathways Are Established for All Stakeholders
Reimbursement Pathways Are Established for All Stakeholders, Including for Both Drug and Session Delivery Annual Cost Spravato® Stakeholder Reimbursement/Coding Activity Local or Telehealth Medical Benefit 3 Up to $1,200 Evaluation & Prescribing 1 Prescriber E&M Code (992XX) or G Code 4 ~$25,000 – 6
Slide 52: MM120 Could Offer Advantages over Spravato
MM120 Could Offer Significant Advantages over Spravato® in both Clinical and Session Delivery Profiles 1 2 MM120 Durability of activity 1 week or less 3 months + Time spent receiving Up to 112 hours ~ 8 to 32 hours treatment / year Number of treatment Up to 56 1 to 4 sessions / year Up to 56 submiss
Slide 53: Spravato Providers Believe MM120 Will Be Preferable on Session Delivery
Current Spravato® Providers Overwhelmingly Believe MM120 Will Be Preferable on Key Attributes of Session Delivery that Drive Adoption ® Spravato Providers Agree % MM120 is easier to arrange/offer than 80% 2 Spravato MM120 REMS will be less time 76% 2,3 consuming than Spravato MM120 is more economica
Slide 54: Spravato Providers Likely To Refer, Prescribe and Administer MM120
® Vast Majority of Current Spravato Providers Indicate They Are Likely To Refer, 1 Prescribe and Administer MM120 92% 84% Current Spravato® Providers Likely to Refer Current Spravato® Providers Likely to Prescribe 2 2 Patient for MM120 and Administer MM120 1. Source: MindMed Primary Market Research
Slide 55: Payer Perspectives on the Potential Value of MM120
Payer Perspectives on the Potential Value of MM120 Predictability of response early Tolerability and compliance Durable reduction of anxiety in treatment course enables profile supports low-waste and comorbidities reduces efficient use of resources budget impact healthcare utilization and cost burde
Slide 56: GAD Has a Major Impact on Employers
GAD Has a Major Impact on Employers by Driving Employee Disengagement and Work Productivity Loss Diagnosed Severe 1 Group Control 2 GAD • Potential impact of MM120 extends beyond direct health benefits and drives broad value Absenteeism 6.0% 21.0% proposition • Employers play important role in Prese
Slide 57: Focused Strategy to Deliver on the Commercial Opportunity
Advancing a Focused Strategy to Deliver on the Commercial Opportunity for MM120 Educate Stakeholders Maximize Access and about GAD & MM120 Reimbursement MM120 Value Proposition Integrate MM120 Session Delivery into Current Infrastructure Investor Presentation | March 2024 57
Slide 58: Summary Comments for MM120 Development Plan
Summary Comments for MM120 Development Plan Robert Barrow Chief Executive Officer
Slide 59: Multiple Studies Support Phase 3 Development of MM120
Multiple Studies Support Phase 3 Development of MM120 1 • Achieved goals of Phase 2 development o Characterized dose-response to inform dose selection in GAD o Large, statistically significant and clinically meaningful effect in GAD o Rapid and durable therapeutic benefits on validated endpoint o St
Slide 60: MM120 Development Pathway
MM120 Development Pathway 1 • Two Phase 3 pivotal clinical trials in planning o 12-week randomized, placebo-controlled primary efficacy study design o Open-label extension to establish retreatment parameters o Expect to initiate Phase 3 development in the second half of 2024 • Key design elements ex
Slide 61: Next Steps and Anticipated Milestones
Next Steps and Anticipated Milestones for MM120 and Pipeline Programs Q1 2024 Q2 2024 Q3 2024 Q4 2024 MM120 GAD MM120 GAD Phase 2b / 12-wk Topline Full data presentation at scientific meeting MM120 GAD Zydis ODT PK Bridging Data MM120 GAD MM120 GAD Phase 3 initiation End-of-Phase-2 meeting w/FDA MM1
Slide 62: Q&A
Q&A Investor Presentation | March 2024
Slide 63: Appendix
<4) MindMed Appendix
Slide 64: HAM-A Response Rate Over Time
1,3 65% HAM-A Response Rate (HAM-A) Achieved at Week 12 2 HAM-A Response Rate Over Time 90 78 78 78 78 80 75 70 68 70 65 63 58 60 56 54 53 51 51 50 49 50 47 44 44 38 40 33 31 31 31 30 20 10 0 Week 1 Week 2 Week 4 Week 8 Week 12 p-values not calculated Placebo 25 µg 50 µg 100 µg 200 µg 1. Source: Stu
Slide 65: HAM-A Remission Rate Over Time
1,3 48% Remission Rate (HAM-A) Achieved through Week 12 2 HAM-A Remission Rate Over Time 60 50 50 48 45 45 45 43 40 38 35 33 33 33 33 33 33 33 31 30 28 28 26 25 21 21 21 20 18 15 10 0 Week 1 Week 2 Week 4 Week 8 Week 12 p-values not calculated Placebo 25 µg 50 µg 100 µg 200 µg 1. Source: Study MMED0
Slide 66: CGI-S Scores Over Time
Statistically Significant Improvement in Clinical Global Impressions – Severity (CGI-S) 1,2 Score Achieved by Day 2 and Sustained through Week 12 CGI-S Scores Over Time 6 – Severely Ill 5 – Markedly Ill 4 – Moderately Ill * *** 3 – Mildly Ill * *** ** *** * * *** * * * *** *** * * ** 2 – Borderline
Slide 67: MADRS Response Rate Over Time
65% Response Rate for Comorbid Depression Symptoms (MADRS) Achieved through 1,3 Week 12 2 MADRS Response Rate Over Time 90 80 78 80 70 70 70 70 65 65 63 58 60 55 54 53 51 50 50 47 46 44 44 44 44 41 40 33 33 33 28 30 20 10 0 Week 1 Week 2 Week 4 Week 8 Week 12 p-values not calculated Placebo 25 µg 50
Slide 68: MADRS Remission Rate Over Time
60% Remission Rate from Comorbid Depression Symptoms (MADRS) Achieved through 1,3 Week 12 2 MADRS Remission Rate Over Time 90 78 80 70 70 63 63 60 60 60 55 55 49 48 48 50 47 46 44 42 42 41 41 39 38 38 40 33 31 28 28 30 20 10 0 Week 1 Week 2 Week 4 Week 8 Week 12 p-values not calculated Placebo 25 µg
Slide 69: Most Common TEAEs Across All Groups
1 Most Common (≥10%) TEAEs Across All Groups MM120 was well tolerated across all dose groups with mostly transient, mild to moderate adverse events MM120 Placebo (n=39) Preferred Term 25 µg 50 µg 100 µg 200 µg (n=39) (n=40) (n=40) (n=40) Subjects (%) with AE DD AFT DD AFT DD AFT DD AFT DD AFT Illusi
Slide 70: Most Common TEAEs Across All Groups (cont)
1 Most Common (≥10%) TEAEs Across All Groups (cont) MM120 was well tolerated across all dose groups with mostly transient, mild to moderate adverse events MM120 Placebo (n=39) Preferred Term 25 µg 50 µg 100 µg 200 µg (n=39) (n=40) (n=40) (n=40) Subjects (%) with AE DD AFT DD AFT DD AFT DD AFT DD AFT
Mind Medicine (MindMed) — Investor Presentation (March 2024) on 6ix